TB-500
Also known as: Thymosin Beta-4 Fragment, TB4-FRAG, Ac-LKKTETQ, Thymosin beta-4 fragment
TB-500 commonly denotes an acetylated seven-residue fragment of thymosin beta-4. Inconsistent research-market labeling makes it essential to distinguish that fragment from the full-length parent and its clinical studies.
Quick Facts
Fragment identity and product labels
A 2012 chemical analysis identified N-acetylated Ac-LKKTETQ, a seven-residue actin-binding fragment, in a tested TB-500 product. The endogenous parent, thymosin beta-4, has 43 amino acids. This finding does not identify every product marketed under the TB-500 name: some labels refer to full-length material or other fragments.
The FDA assessment separates the fragment, its acetate and the parent peptide. Their chemical identities and regulatory histories are not interchangeable.
Actin and proposed repair mechanisms
Proposed fragment actions include actin binding, cell migration, angiogenesis and inflammation modulation. Reviews of the full-length peptide also discuss stem/progenitor-cell mobilization and reduced scarring across skin, eye, cardiac and nervous-system repair models.
A 2003 experiment found angiogenic and migration-related activity in the seven-residue motif and in full-length thymosin beta-4. Sequence, acetylation, formulation and assay conditions matter. Much of the marketed recovery rationale is extrapolated from parent-peptide animal research rather than demonstrated human fragment benefit.
Fragment research and separate parent trials
No completed peer-reviewed human efficacy program or published human safety program for the synthetic fragment is described through September 2026. FDA identified no clinical exposure or pharmacokinetic data for the evaluated fragment forms.
A 2026 repaired-rat Achilles experiment assigned 32 rats to four groups, with 30 days of intraperitoneal treatment and four tendons per endpoint in each group. The arm labeled TB-500 improved maximum load and selected tissue scores versus control. The combination did not outperform the individual arms. Product identity and human translation remain unresolved.
| Full-length parent study | Finding and boundary |
|---|---|
| Venous-ulcer dose escalation | Early safety/tolerability research, not a TB-500 treatment result. |
| Nine-person RGN-259 eye-drop trial | Favorable discomfort and corneal-staining findings. |
| 72-person RGN-259 trial | Both primary endpoints were unmet; selected secondary outcomes favored treatment. |
| Neurotrophic-keratopathy Phase III, reported 2022; 18 participants | Healing at four weeks: 60% versus 12.5%; p = 0.0656, not conventionally significant. |
These topical ocular and parent-peptide results do not validate injected TB-500. Marketed recovery efficacy remains unproven in people.
US regulatory and anti-doping context
TB-500 has no FDA approval. Following nomination withdrawal it was removed from Category 2 in April 2026, but was not added to Category 1 or the 503A bulks list. Withdrawal was not a safety determination or restoration of compounding eligibility.
On July 23, 2026, PCAC voted 8–6 with one abstention to recommend TB-500 free base and acetate for wound healing on the 503A list. The recommendation was nonbinding and required FDA adoption or rulemaking. It did not immediately authorize pharmacy compounding. The meeting account concerns the fragment, not full-length thymosin beta-4. The described position provides no routine licensed-US-compounding pathway.
The 2026 WADA list prohibits thymosin beta-4 and derivatives, including TB-500, at all times under Section S2.
Dosing, detection and combinations
No general human fragment dose, loading phase, maintenance cycle, local-versus-systemic injection rule, refrigerated expiry or human half-life is established. Horse and rat exposure/detection studies cannot define a human injection interval or replace finished-product preparation and stability evidence. Parent-peptide tolerability cannot establish fragment or combination safety. FDA identifies characterization and immunogenicity uncertainties without proving that every exposure causes harm.
Analytical methods were published for equine urine and plasma in 2012; a 2024 equine-population study explored detection of thymosin beta-4 misuse. A doping laboratory also proposed fragment detection in plasma and urine. Detection research is not efficacy research.
TB-500 and BPC-157 differ in sequence, origin and proposed mechanism. Neither has completed human musculoskeletal efficacy trials or a validated combined protocol. A small knee-pain chart review contacted four BPC-157 plus TB4 recipients; three reported improvement. TB4 identity was not established as commercial Ac-LKKTETQ, and no controlled comparator was used. Alongside the small rat comparison, that supports further study rather than proven synergy or same-syringe compatibility.
References and further reading
This reference draws on Superpower’s Peptide Library and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .
- 10.1517/14712598.2012.634793Actin and proposed repair mechanismsCited in: Actin and proposed repair mechanisms
- mcdermottlaw.comUS regulatory and anti-doping contextCited in: US regulatory and anti-doping context
- pubmed.ncbi.nlm.nih.govFragment research and separate parent trialsCited in: Fragment research and separate parent trials
- pubmed.ncbi.nlm.nih.govFragment research and separate parent trialsCited in: Fragment research and separate parent trials
- 10.1196/annals.1415.003Fragment research and separate parent trialsCited in: Fragment research and separate parent trials
- pubmed.ncbi.nlm.nih.govFragment identity and product labelsCited in: Fragment identity and product labels
- fda.govUS regulatory and anti-doping contextCited in: US regulatory and anti-doping context
- pubmed.ncbi.nlm.nih.govDosing, detection and combinationsCited in: Dosing, detection and combinations
- pubmed.ncbi.nlm.nih.govDosing, detection and combinationsCited in: Dosing, detection and combinations
- statnews.comUS regulatory and anti-doping contextCited in: US regulatory and anti-doping context
- www.fda.gov — additional readingFragment identity and product labelsCited in: Fragment identity and product labels
- pubmed.ncbi.nlm.nih.gov — additional readingActin and proposed repair mechanismsCited in: Actin and proposed repair mechanisms
- jointdrs.org — additional readingFragment research and separate parent trialsCited in: Fragment research and separate parent trials
- pubmed.ncbi.nlm.nih.gov — additional reading
- pubmed.ncbi.nlm.nih.gov — additional reading
- www.wada-ama.org — additional readingUS regulatory and anti-doping contextCited in: US regulatory and anti-doping context
- pubmed.ncbi.nlm.nih.gov — additional readingDosing, detection and combinationsCited in: Dosing, detection and combinations
Frequently Asked Questions About TB-500
BPC-157 and the TB-500 fragment have different identities and experimental findings. Their mechanisms do not establish a local-versus-systemic treatment rule or a proven combination advantage.
The reviewed evidence does not establish a human injury-targeting injection rule for either compound. Animal or parent-peptide findings cannot identify the best fragment route or site in people.
No dependable human fragment timeline is established. Animal follow-up periods and uncontrolled reports cannot create a standard 4–8 week recovery course.
Yes. The 2026 WADA list prohibits thymosin beta-4 and derivatives including TB-500 at all times for athletes subject to those rules.
No. Ac-LKKTETQ is an acetylated seven-residue fragment; full-length thymosin beta-4 has 43 residues. Human eye and ulcer trials studied the parent. A commercial name alone cannot verify vial identity.
It has no FDA approval. Removal from Category 2 after nomination withdrawal did not place it in Category 1 or on the 503A bulks list. The favorable July 2026 vote did not itself authorize compounding.
The described regulatory position provides no routine pharmacy pathway. Research-market products for human use remain outside normal regulated pharmaceutical oversight.
They have different structures and proposed actions. Both were described as nominated but withdrawn in September 2026, neither was on the 503A bulks list, and no clinically validated combined musculoskeletal protocol is established.
Methods have detected TB-500 or related fragments in biological samples, including equine urine and plasma. WADA prohibits use both in and out of competition; laboratory detection work does not establish a safe-use window.
No completed peer-reviewed fragment efficacy trial is described through September 2026. The 18-person ocular trial reporting 60% versus 12.5% healing at four weeks (p = 0.0656) used full-length thymosin beta-4 eye drops, not systemic TB-500.
Nomination withdrawal, removal from Category 2 and the 8–6 advisory recommendation were distinct from effective FDA rulemaking. Other peptides have their own histories; that vote alone did not create 503A authorization.
The described position has neither an approved product nor Category 1 or 503A bulks-list inclusion. A prescription alone does not create lawful compounding eligibility. Administration in authorized research is a separate setting.
Related Peptides
Continue exploring TB-500
- BPC-157 + TB-500 Blend: Evidence & Combination Questions [2026]Guide
- BPC-157 vs TB-500: Evidence & Wolverine Stack Questions [2026]Comparison
- GLOW Peptide Blend: GHK-Cu, BPC-157 & TB-500 Dosage Guide [2026]Guide
- KLOW Peptide Blend: GHK-Cu, BPC-157, TB-500 & KPV Guide [2026]Guide
- PCAC Vote Results: FDA Panel Backs 6 of 7 Peptides for 503A Compounding [2026]Guide
- Peptides for Injury Recovery: BPC-157, TB-500, GHK-Cu & Growth FactorsGuide
- Peptides for Joint Pain: BPC-157, TB-500 & Collagen PeptidesGuide
- Recovery & Healing Peptides: BPC-157, TB-500 & More [2026 Guide]Topic
Our library review is ongoing. Read how we evaluate evidence or report a correction.
Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.